TY - JOUR
T1 - Acute Myeloid Leukemia
T2 - from Mutation Profiling to Treatment Decisions
AU - DiNardo, Courtney
AU - Lachowiez, Curtis
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose of Review: Awareness of the molecular landscape of AML has improved AML care over the last 5 years. This review summarizes updates regarding the diagnostic and therapeutic relevance of key mutations in AML. Recent Findings: Molecular mutations in genes including NPM1, CEBPA, FLT3, IDH1/2, TP53, RUNX1, and ASXL1 provide important prognostic and/or therapeutic information in AML, including best treatment strategies, transplant recommendations, and significance of MRD detection. Mutational analysis has led to the recognition of new entities including hereditary leukemia syndromes and clonal hematopoiesis of indeterminate potential (CHIP). FLT3 and IDH1/2 mutations are the focus of targeted therapies in the treatment of AML. Summary: Advances in the molecular characterization of AML have provided an improved understanding of leukemogenesis and AML risk stratification, improved disease monitoring techniques, optimized therapeutic strategies, and have led to the development of novel molecular-targeted therapeutics. Ongoing genomic advances will continue to improve upon the outcome of patients with AML.
AB - Purpose of Review: Awareness of the molecular landscape of AML has improved AML care over the last 5 years. This review summarizes updates regarding the diagnostic and therapeutic relevance of key mutations in AML. Recent Findings: Molecular mutations in genes including NPM1, CEBPA, FLT3, IDH1/2, TP53, RUNX1, and ASXL1 provide important prognostic and/or therapeutic information in AML, including best treatment strategies, transplant recommendations, and significance of MRD detection. Mutational analysis has led to the recognition of new entities including hereditary leukemia syndromes and clonal hematopoiesis of indeterminate potential (CHIP). FLT3 and IDH1/2 mutations are the focus of targeted therapies in the treatment of AML. Summary: Advances in the molecular characterization of AML have provided an improved understanding of leukemogenesis and AML risk stratification, improved disease monitoring techniques, optimized therapeutic strategies, and have led to the development of novel molecular-targeted therapeutics. Ongoing genomic advances will continue to improve upon the outcome of patients with AML.
KW - Acute myeloid leukemia
KW - Minimal residual disease
KW - Molecular prognostication
KW - Risk stratification
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85069819027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069819027&partnerID=8YFLogxK
U2 - 10.1007/s11899-019-00535-7
DO - 10.1007/s11899-019-00535-7
M3 - Review article
C2 - 31350639
AN - SCOPUS:85069819027
SN - 1558-8211
VL - 14
SP - 386
EP - 394
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 5
ER -